Leniolisib

Leniolisib (CDZ173) is a potent and selective PI3Kδ inhibitor. Leniolisib has the potential for immunodeficiency disorders treatment.

Product Specifications

CAS Number

[1354690-24-6]

Product Name Alternative

CDZ173

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

PI3K

Type

Reference compound

Related Pathways

PI3K/Akt/mTOR

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/Leniolisib.html

Purity

99.38

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

CCC(N1C[C@@H](NC2=C(CN(C3=CC(C(F)(F)F)=C(OC)N=C3)CC4)C4=NC=N2)CC1)=O

Molecular Formula

C21H25F3N6O2

Molecular Weight

450.46

Precautions

H302, H315, H319, H335

References & Citations

[1]Rao V, et al. Effective 'Activated PI3Kd Syndrome' -targeted therapy with PI3Kd inhibitor leniolisib. The New England journal of medicine: NEJM. ISSN 0028-4793; 1533-4406|[2]Hoegenauer K, et al. Discovery of CDZ173 (Leniolisib), Representing a Structurally Novel Class of PI3K Delta-Selective Inhibitors. ACS Med Chem Lett. 2017 Aug 25;8 (9) :975-980.